Medical Sector

Citation:

Taher, A., M. S. Elalfy, K. A. Zir, S. Daar, A. A. Jefri, D. Habr, U. Kriemler-Krahn, A. El-Ali, B. Roubert, and A. El-Beshlawy, "Importance of Optimal Dosing ? 30 mg/kg/d During Deferasirox Treatment: 2", European Journal of Haematology, 2011.

Abstract:

Following 1-yr deferasirox therapy in the ESCALATOR study, 57% of previously chelated patients with ?-thalassaemia achieved treatment success (maintenance of or reduction in liver iron concentration (LIC) vs. baseline LIC). Seventy-eight per cent had dose increases at median of 26 wk,

Notes:

n/a